|
Adenoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Moreover, in two distinct CRC mouse models, loss of Mpc1 prior to a tumorigenic stimulus doubled the frequency of adenoma formation and produced higher grade tumors.
|
31813825 |
2020 |
|
Neoplasms
|
0.050 |
AlteredExpression
|
group |
BEFREE |
Consistently, KDM5A expression was elevated in PDA and promoted PDA cell proliferation in vitro and tumor growth in vivo via suppressing the expression of MPC-1.
|
31641207 |
2020 |
|
Neoplasm Metastasis
|
0.040 |
AlteredExpression
|
phenotype |
BEFREE |
The expression of MPC-1 was decreased in PDA cell lines and tissues, and negatively associated with tumor poorer differentiation, lymph nodes metastasis, higher TNM stages, and patients' overall survival (OS).
|
31641207 |
2020 |
|
Patent ductus arteriosus
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients.
|
31641207 |
2020 |
|
PATENT DUCTUS ARTERIOSUS 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
TCGA database, paired PDA and adjacent normal pancreatic tissues, PDA tissue array and cell lines were used to determine the levels of MPC-1 and KDM5A expression, and their relationship with the clinicopathologic characteristics and overall survival (OS) of PDA patients.
|
31641207 |
2020 |
|
Multiple Myeloma
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
MPC-1 expression in myeloma cells is associated with the efficacy of bortezomib therapy.
|
31342211 |
2019 |
|
Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
A total of 631 patients with glioblastoma (mean age 57.78 ± 14.36 years, 59% of males) were examined in this study, including 438 cases with MPC1 intact (MPC1 copy number segments > - 0.1, 69.4%) and 157 cases with MPC1 deletion (24.9%) tumors.
|
31236818 |
2019 |
|
Glioblastoma
|
0.030 |
Biomarker
|
disease |
BEFREE |
Among the four GBM subtypes, the proneural group had the highest MPC1 copy number segments and GBM patients diagnosed with proneural subtype showed the best outcome.
|
31236818 |
2019 |
|
Adult Glioblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A total of 631 patients with glioblastoma (mean age 57.78 ± 14.36 years, 59% of males) were examined in this study, including 438 cases with MPC1 intact (MPC1 copy number segments > - 0.1, 69.4%) and 157 cases with MPC1 deletion (24.9%) tumors.
|
31236818 |
2019 |
|
Childhood Glioblastoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
A total of 631 patients with glioblastoma (mean age 57.78 ± 14.36 years, 59% of males) were examined in this study, including 438 cases with MPC1 intact (MPC1 copy number segments > - 0.1, 69.4%) and 157 cases with MPC1 deletion (24.9%) tumors.
|
31236818 |
2019 |
|
Glioblastoma Multiforme
|
0.030 |
Biomarker
|
disease |
BEFREE |
Among the four GBM subtypes, the proneural group had the highest MPC1 copy number segments and GBM patients diagnosed with proneural subtype showed the best outcome.
|
31236818 |
2019 |
|
Hamartoma Syndrome, Multiple
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In this study, we carried out following mRNA expression profile analysis on Cd-treated <i>mpc1-1</i> and wild-type plants.
|
31198086 |
2019 |
|
Multiple Myeloma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Clinical effects of CD33 and MPC-1 on the prognosis of multiple myeloma treated with bortezomib.
|
30887866 |
2019 |
|
Malignant Neoplasms
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Decreased MPC1 expression favorably affects EMT and radioresistance of cancer.
|
30801869 |
2019 |
|
Primary malignant neoplasm
|
0.040 |
AlteredExpression
|
group |
BEFREE |
Decreased MPC1 expression favorably affects EMT and radioresistance of cancer.
|
30801869 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
Collectively, we reveal that MPC1/STAT3 axis plays an important role in the progression of LAC, and our work may promote the development of new therapeutic strategies for LAC.
|
30770798 |
2019 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Mitochondrial pyruvate carrier 1 (MPC1), a key factor that controls pyruvate transportation in the mitochondria, is known to be frequently dysregulated in tumor initiation and progression.
|
30770798 |
2019 |
|
Dermatomyositis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Diabetes Mellitus
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Lung Diseases, Interstitial
|
0.010 |
AlteredExpression
|
group |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
MYOTONIC DYSTROPHY 1
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This study aims to detect serum levels of monocyte chemoattractant protein-1 (MPC-1) and transforming growth factor-β1 (TGF-β1) in polymyositis/dermatomyositis (PM/DM) patients complicated with interstitial lung disease (ILD), to reveal the significance of the changes in these levels in the pathogenesis of PM/DM complicated with ILD.
|
30764873 |
2019 |
|
Neoplasms
|
0.050 |
Biomarker
|
group |
BEFREE |
Mitochondrial pyruvate carrier 1 functions as a tumor suppressor and predicts the prognosis of human renal cell carcinoma.
|
30291323 |
2019 |
|
Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results identify anti-tumor function of MPC1 in RCC and revealed MPC1 as a novel prognostic biomarker to predict better patient survival.
|
30291323 |
2019 |
|
Conventional (Clear Cell) Renal Cell Carcinoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Taken together, our results identify anti-tumor function of MPC1 in RCC and revealed MPC1 as a novel prognostic biomarker to predict better patient survival.
|
30291323 |
2019 |
|
Glioblastoma
|
0.030 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the inhibition of COUP-TFII was able to increase MPC1 expression and inhibit the growth of glioblastoma cells <i>in vitro</i> and <i>in vivo</i>.
|
29928345 |
2018 |